Bosnian Journal of Basic Medical Sciences · 2019 · 21 citations · 13 references
MedicineOncologyPathologyCancer ImmunologyMetastasisTumor ImmunologyBrain MetastasesBrain MetastasisCancer BiomarkersImmuno-oncology BiomarkersLung CancerTumor MarkersCancer Metastasis BiomarkersCd8+ Tumor-infiltrating LymphocytesImmune Biomarkers In CancerPredictive Biomarker AssessmentPredictive Biomarker DevelopmentPredictive Biomarker ValidationProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 Biomarker
Programmed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-small-cell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially brain metastasis (BM), remains unclear. This study assessed the concordance of PD-L1 expression on tumor cells and tumor-infiltrating lymphocytes (TILs) and CD8+ TIL intensity between primary lung tumors and synchronous BMs from 24 NSCLC patients. PD-L1, CD3, and CD8 positivity was determined by immunohistochemistry (IHC). PD-L1 scoring was based on the proportion of tumor cells with membranous expression of PD-L1 and the cutoff values <1%, 1-49%, and ≥50%. CD3 and CD8 positivity in TILs was evaluated semi-quantitatively and the proportion of CD3+/CD8+ TILs was determined. PD-L1 expression on tumor cells and TILs was evaluated in relation to CD3+/CD8+ TIL proportions and the intensity of CD8+ TILs between the paired primary lung and BM tissues. In the primary lung tumors, PD-L1 positivity was observed in 25%, 37.5%, and 37.5% cases for the cutoff values <1%, 1-49%, and ≥50%, respectively. PD-L1 expression on tumor cells was strongly correlated between the paired primary lung and BM tissues, in all cutoff groups. However, PD-L1 expression on TILs and the proportion of CD3+/CD8+ TILs were not strongly correlated in all three groups between the paired primary lung tumors and BMs. The intensity of CD8+ TILs was concordant in only 54.16% of the paired primary lung tumors and BMs. This study showed a high concordance of PD-L1 expression in neoplastic cells between primary NSCLC and synchronous BMs.
13
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel, Guido Kroemer · OncoImmunology · 2012 · 374 citations · Full text
Life Sciences, Immunology, Oncology +17
Aaron S. Mansfield, MC Aubry, Justin C. Moser et al. · Annals of Oncology · 2016 · 336 citations · Full text